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The elastase content of neutrophils is very high, i.e. 46 #g per 10 s cells, or 1.2 
x  107  molecules/cell (1).  The enzyme, which is localized in  granules (2),  is a 
serine proteinase; it functions optimally at the neutral pH of extracellular fluids 
(3).  Neutrophil  elastase  has  broad  substrate  specificity,  capable  of cleaving 
fibrinogen  (4),  fibronectin (5),  immunoglobulin  (6),  plasminogen  (7),  growth 
factors (8), complement (9), and coagulation factors (10), as well as the extracel- 
iular structural components elastin,  cartilage proteoglycans (11),  and  type III 
collagen (12,  13),  Elastase of circulating monocytes appears  to be identical to 
neutrophil elastase (14); the enzyme is present at 30-fold lower levels in mono- 
cytes (1, 14). Much of the attention focused on neutrophil and monocyte elastase 
has  emphasized  its  pathological  roles,  e.g.  in  the  development of pulmonary 
emphysema (15) and in arthritic lesions (16).  A  physiological role was demon- 
strated for elastase of neutrophils as a fibrinolytic agent in circulating blood (1). 
Moreover, neutrophil elastase was recently found to play a role in the migration 
of phagocytes from the circulation into inflammatory sites, i.e., it was shown that 
elastase activity is required for the chemotactic movement of neutrophils through 
an amnion membrane (17) or through an endothelial cell barrier (18), but is not 
required for movement through an artificial barrier. 
Elastase is clearly a potent proteinase; pathological effects would be anticipated 
in the absence of regulation. In circulation, released elastase is found in inactive 
form complexed to the plasma inhibitor a~-proteinase inhibitor (a~PI,  ~-anti- 
trypsin)  ~ and to a lesser extent to a2-macroglobutin (19). At inflammatory sites, 
phagocytes,  i.e.  monocyte/macrophages and  especially neutrophils,  have  the 
capacity to generate high local concentrations of elastase. It is thought (20, 21) 
that neutrophil elastase at inflammatory sites is inactivated by a~PI from circu- 
lating blood plasma, and possibly from macrophages (22).  A  second possibility 
for  regulating  elastase  activity at  inflammatory sites  is  alteration  in  the  cell 
content of the proteinase itself.  The serine elastase content of monocytes de- 
creases as  the  cells  develop  macrophage-like  characteristics  (23).  This  study 
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describes  a  third  capability  for  regulation  of elastase  activity at  inflammatory 
sites.  We present  the  first characterization  of a  fast-acting inhibitor  of elastase 
present in high concentrations in human monocytes. 
Materials and  Methods 
Monocytes.  Monocytes were  purified  from freshly-drawn  blood anticoagulated  with 
acid  citrate-dextrose  obtained  from  Children's  Hospital  Medical  Center  Blood  Bank 
(Boston, MA). The blood was centrifuged in the collection bag at 2,500 rpm for 3 min in 
a  Sorvall  HG rotor.  The blood bag was placed under  pressure  in  a  plasma extractor 
(Fenwal Labs, Deerfield,  IL), and after removal of the platelet-rich plasma, 80  ml was 
expressed from the top of the packed cells (buffy coat) and diluted with equal volume 
Ca++/Mg÷+-free Hanks' balanced salt solution (HBSS) with 20-50 #g]ml leupeptin.  All 
salt solutions and media contained  100 U/ml penicillin and  100 #g/ml streptomycin. 20 
ml portions of buffy coat cells were layered onto 17 ml Ficoll/Hypaque and fractionated 
by centrifugation. The interface cells (mononuclear cells) were washed by 1-4 cycles of 
suspending and pelleting at room temperature in Ca++/Mg++-free HBSS with  2%  fetal 
calf serum  (FCS)  to  reduce  platelet  contamination  to  negligible  levels,  as judged  by 
opalescence and microscopic examination. 
Monocytes were purified on Percoll gradients;  1-2.5 X l0  s washed mononuclear cells 
at  2-5  X  107  cells/ml  in  RPMI  1640  were  layered onto  37  ml  Percoll gradients and 
centrifuged at 4°C (24).  The upper band cells were pelleted twice in RPMI  1640  with 
2% FCS at 4°C. This fraction, designated 0-day monocytes, contained the monocytes in 
97% average yield as judged by Wright's stain and peroxidase stain (25);  the monocyte 
content in four preparations was 40, 83, 56, and 59%, based on peroxidase staining. 
The monocyte preparations were cultured at 2 x  106 cells/ml in RPMI 1640 with 10% 
FCS as nonadherent cells in Teflon beakers (Nalge Co., Rochester, NY); the medium was 
partially replenished every 2  d.  After  1-10 d  the cell suspension was brought to room 
temperature and pelleted. 
Adherence-purified monocytes, used in selected experiments, were prepared by cultur- 
ing mononuclear cells (2.0  x  107 in 5  ml RPMI with  10%  FCS) in 60 X  15-mm tissue 
culture dishes (3002;  Falcon Labware, Oxnard, CA) for 2 h at 37°C. Nonadherent cells 
were decanted, and the monolayers were washed twice in warm RPMI with 2% FCS. The 
adherent monocytes were harvested with or without 7 d culture in RPMI with 10% FCS 
by collecting the cells into cold HBSS with the aid of a rubber policeman and pelleting. 
Lymphocytes.  Lymphocytes were purified by culturing washed mononuclear cells for 1 
h  at  5  ×  106 cells/ml in  RPMI  1640  with  2%  FCS  in plastic tissue culture  flasks;  the 
nonadherent cells (lymphocytes) were washed by pelleting. 
Neutrophils.  The Ficoll-Hypaque pellet was suspended in HBSS and combined with 
an equal volume of 2% dextran in 0.15 M NaCI. After the erythrocytes had sedimented 
(45  min)  the  neutrophils  were  removed  and  washed  by  pelleting  in  HBSS;  residual 
erythrocytes were removed by lysis in water. 
Cell Lines.  The human histiocytic lymphoma cell line U937  (26,  27), donated by D. 
Liu (Brigham and Women's Hospital, Boston, MA), was grown in RPMI in 1640 medium 
with  10%  FCS and 0.1%  gentamycin. The human  lymphoblastoid cell line  CEM  (28), 
donated by H. Lazarus (University of Miami Medical School, Miami, FL), was grown in 
Dulbecco's modified  Eagle's  medium  with  4.5  mg/ml  glucose,  10%  FCS,  100  U/ml 
penicillin, and 100 t~g/ml streptomycin. CEM and U937 cells were washed before use by 
pelleting three times in HBSS. 
Lysis of Cells.  Cells were washed at room temperature (rather than 4°C) in an effort 
to maximize removal of serum cqPI. As a final wash, cells were incubated at 0.5-2 x  107 
cells/ml for 5-10  min in  HBSS at room temperature;  they were brought to 4°C  and 
pelleted. Detergent lysates were prepared by extracting 2.5 x  107 cells with 1 mi of 0.5% 
Nonidet P-40 (NP-40) in phosphate-buffered saline (PBS).  Lysates were clarified (20,000 
g for 13 min) and stored at -80°C. 
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human neutrophil elastase by the lodogen method (29), removal of excess reagents, and 
evaluation of products were described (30).  ~51 label associated with protein was found 
to be >90% covalently bound. Protein concentration was determined by the Folin method 
(31). The products, ~25I-labeled porcine pancreatic elastase with 0.5-1.5/~Ci/~g and ~25I- 
labeled human neutrophil elastase with 1-3 #Ci//~g were stored in portions at -20°C. 
Formation of 125I-Elastase-Inhibitor Complex.  Cell extracts (! 5-150 #i) were incubated 
with 30-200 ng of '2~I-elastase in 20 #i of HBSS at 37°C for 20 min; typical reactions 
contained 60/~1 cell extract from 1.5 ×  106 cells with 130 ng ~25I-labeled  porcine pancreatic 
elastase. The reaction was simultaneously stopped and the mixture prepared for electro- 
phoresis by adding 40 ~1 sodium dodecyl sulfate (SDS) solubilizing solution (5% SDS, 25% 
glycerol, 100 ~g/ml bromophenol blue, 8% mercaptoethanol)and heating at 100°C for 
1 min. Alternatively, the incubation mixtures were immediately subjected to immunopre- 
cipitation. 
Immunoprecipitation.  The immunoprecipitating particles, fixed Staphylococcus aureus 
coated with rabbit antiserum  to a~PI or with normal  rabbit serum, were prepared as 
described (32).  The particles were incubated with the preformed ~25I-elastase-inhibitor 
complexes for 60  min  at  room  temperature.  The  resulting  bacteria-antibody-antigen 
complexes were  washed  (32)  and  extracted at  100°C  for  1 min  with  190  #1 of SDS 
solubilizing solution diluted 1:3 with PBS. 
SDS Polyacrylamide Gel Electrophoresis (PAGE).  For Laemmli SDS electrophoresis (33), 
the 2.2-mm resolving slab gels were prepared from 370 mM Tris HCI buffer, pH  8.8, 
7.5%  acrylamide,  0.2%  bisacrylamide,  0.1%  SDS.  The  modified  stacking  gels  were 
prepared from 60 mM  Tris HCI buffer, pH  6.8,  4% acrylamide, 0.1%  bisacrylamide, 
0.3% SDS. Running buffer was 42 m M Tris/190 mM glycine buffer, pH 8.3, with 0.1% 
SDS. 
For  Fairbanks/Laemmli  SDS  electrophoresis,  the  procedure  (34)  was  modified  to 
generate 2.2-mm resolving slab gels prepared from 40 mM Tris acetate buffer, pH 7.4, 
2 mM EDTA, 6% acrylamide, 0.2% bisacrylamide, 1% SDS. Stacking gels were included 
as described for Laemmli electrophoresis. Running buffer was 40 mM Tris acetate buffer, 
pH 7.4, 2 mM EDTA, 1% SDS. 
The  standard  proteins,  myosin,  /3-galactosidase,  phosphorylase a,  albumin,  creatine 
kinase, carbonic anhydrase, and soybean trypsin inhibitor indicated tool wt of 200,000, 
130,000, 94,000, 68,000, 40,000, 29,000, and 22,000, respectively. Gels were dried and 
subjected to autoradiography. 
Materials and Suppliers.  The sources of materials are as follows: NP-40 (BDH Chem- 
icals,  Ltd., Poole, United Kingdom); Nal~5I (Amersham Corp., Arlington Heights, IL); 
Iodogen (Pierce Chemical  Co.,  Rockford, IL);  Percoll (colloidal polyvinyipyrrolidone- 
coated silica, P-1644; Sigma Chemical Co., St. Louis, MO); intensifying screens (Cronex 
Lightning Plus;  E. I. Dupont de Nemours Co., Wilmington, DE); N,N'-methylene bisac- 
rylamide and acrylamide (Bio-Rad  Laboratories, Richmond,  CA);  formaldehyde-fixed, 
heat-killed Staphylococcus aureus  (The Enzyme Center,  Boston,  MA);  Ficoll-Paque and 
Sephadex G-25 (Pharmacia Fine Chemicals, Piscataway, NJ); and acid citrate-dextrose, 
National Institutes of Health formula A (Fenwal Laboratories, Deerfield, IL). 
HBSS and Ca++/Mg++-free  HBSS, RPMI  1640, Dulbecco's modified Eagle's medium, 
penicillin, streptomycin, and fetal bovine serum were from M. A. Bioproducts, Walkers- 
ville, MD. Serum was heat-inactivated (fi6°C for 1 h). PBS was from Gibco Laboratories, 
Grand Island, NY, and gentamycin sulfate from U. S. Biochemical Corp., Cleveland, OH. 
Homogeneous  porcine  pancreatic  elastase  (95-125  U/mg)  and  human  neutrophil 
elastase purified from purulent human sputum (35) were from Elastin Products Co., Inc., 
Pacific, MO. N-acetyl-Ala-Ala-Pro-Ala-CH~CI  was kindly supplied by J. Powers (Georgia 
Institute of Technology). p-(amidinophenyl)methanesulfonyl fluoride (pAMPSF) was ob- 
tained from Chemicon International, Inc., El Segundo, CA.  One of the rabbit antisera 
against ~PI was kindly supplied by C. Alper (The Center for Blood Research); another 
antiserum was from Dako Corp., Santa Barbara, CA. REMOLD-O'DONNELL  2145 
Results 
Detection of Elastase Inhibitor in a Monocyte-like Cell Line.  Based on the detec- 
tion of an elastase inhibitor in macrophages of guinea pigs (30) we hypothesized 
that human monocytes/macrophages contain a proteinase inhibitor active against 
elastase.  Most  circulating  blood  proteinase  inhibitors,  as  well  as  the  cellular 
proteinase  inhibitor  of guinea  pig  macrophages  have  the  common  feature  of 
forming covalent complexes with serine active site proteinases (36). A  molecule 
that forms a complex with ~25I-labeled pancreatic elastase was detected in extracts 
of the human  monocyte-like cell line U937, but was not detected in extracts of 
the human lymphoblastoid cell line CEM (Fig.  1, A-C). 
We  conclude  that  the  integrity  of the  active  site  of elastase  is  required  for 
complex formation with the U937 component because the reaction is inhibited 
by diisopropylfluorophosphate, a serine active site inhibitor, and by N-acetyl-Ala- 
Ala-Pro-Aia-chloromethyl  ketone, which binds to the elastase active site, but not 
by pAMPSF, which binds to the active site of arginine-containing  serine protein- 
ases  (Fig.  1,  D-G).  Formation  of the  complex  is  inhibited  by  20-fold  excess 
nonradiolabeled elastase, but not by 20-fold excess ovalbumin (not shown). The 
ability  of the  component  in  U937  cell  extracts  to  form  a  complex  with  125I- 
elastase is destroyed by boiling in SDS (not shown). The preformed complex, on 
the other  hand,  is stable when  heated in  SDS,  suggesting that  the linkage  is a 
covalent bond. Bases such as ammonium hydroxide (37) are known to hydrolize 
ester bonds of serine proteinase-proteinase  inhibitor  complexes.  The complex 
of the  U937  component  with  ~SI-elastase is cleaved on incubation  with  1.5  M 
ammonium hydroxide at 37 °C for 60 min (Fig.  1, H-K), further indicating that 
the complex is a proteinase-proteinase inhibitor covalent complex. The complex 
of the U937 proteinase inhibitor with ~25I-elastase comigrates on Laemmli SDS- 
FIGURE  1.  A-C,  reaction of ~2~I-labeled porcine pancreatic elastase with a  component of 
human cell lines. Shown is an autoradiograph of a  Laemmli SDS-PAGE gel of 33  ng  t~sI- 
elastase incubated with: A, nQ additives; B,  the extract of 1.5  ×  I06  U937 cells; and C, the 
extract of  1.5  ×  106  CEM  cells.  Arrow indicates the  ~SI-elastase-inhibitor complex of Mr 
66,000; E designates unreacted ~Sl-elastase. D-G, effect of synthetic inhibitors on the reaction 
of ~SI-pancreatic elastase with the component in U937 cells.  The U937 extract was reacted 
with ~SI-elastase that had been preincubated for 20 rain at 30°C with: D, no additives; E, 2 
mM diisopropylfluorophosphate;  F, 500 #M N-acetyl-Ala-Ala-Pro-Ala-CH~Cl;  and G, 500 #M 
p-AMPSF. The agents introduced as solvents for the synthetic inhibitors (2% ethanol, 0.2% 
propylene glycol) did not inhibit complex formation (not shown). H-K, cleavage ofttie complex 
by ammonium hydroxide. Shown is an autoradiograph of a  Fairbanks/Laemmli SDS-PAGE 
gel of the U937 extractJ25I-pancreatic elastase reaction product, which underwent a second 
incubation for 60 min with: H, PBS at 4°C; I, PBS at 37°C;J,  1.5 M NH4OH at 4°C; and K, 
1.5  M  NH4OH  at  37°C.  Diisopropylfluorophosphate at  1  mM  was  added  to  all  reaction 
mixtures before the second incubation to prevent proteolysis of the complex. 2146  A  FAST-ACTING  ELASTASE  INHIBITOR  IN  HUMAN  MONOCYTES 
PAGE with the complex of 125I-elastase with the guinea pig macrophage protein- 
ase inhibitor  (MPI)  (30)  at Mr  66,000  (not shown),  suggesting that  these are 
analogous molecules from different species. 
Dose Dependence of Complex-formation Assay.  The amount of the l~5I-elastase- 
inhibitor  complex  generated  was  found  to  depend  on  the  amount  of U937 
extract added (Fig. 2 A). The complex and unreacted 125I-elastase were quantified 
by gamma counting after excision from SDS-polyacrylamide gels.  Plots of the 
percent of 125I-elastase converted to complex vs.  the amount of extract added 
gave  dose-response  curves  (Fig.  2B),  thus  establishing  that  the  12~I-elastase 
complex  formation  reaction  can  be  used  as  a  semiquantitative  assay  for  the 
proteinase inhibitor. 
Elastase Inhibitor in Blood Cells.  Isolated blood cells were lysed and examined 
for their content of inhibitor by the 2~5I-pancreatic e|astase complex formation 
assay.  Compared  to  U937  cell  extracts,  activity  was  minimal  in  lymphocyte 
extracts, and not detectable in neutrophils (Fig. 3). Surprisingly, elastase inhibitor 
activity was not detected in extracts of Percoll-purified monocytes (Fig. 3). 
Appearance  of Elastase  Inhibitor in Monocytes Matured  in  Culture.  We  ques- 
tioned  whether  the  elastase  inhibitor  is  expressed  by  monocytes  that  have 
acquired macrophage-like properties by in vitro culture. Percoll-purified mono- 
cytes  were  allowed  to  mature  in  culture.  The  elastase  inhibitor  activity  of 
FIGURE 2.  Effect of the concentration of U937 extract on the extent of complex formation 
with 12~l-pancreatic elastase. Shown in A is an autoradiograph of a  Fairbanks/Laemmli SDS- 
PAGE gel of 97 ng ~eSI-elastase reacted with varying amounts of U937 extract, as indicated. 
Arrow  indicates the  ~25I-elastase-inhibitor  complex of Mr  66,000;  E  designates unreacted 
elastase. B shows quantitation of  the complex measured by gamma counting of  the t~SI-complex 
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FIGURE 3.  Reaction of extracts of human blood cells with l~5I-pancreatic elastase. Shown is 
125  an  autoradiograph of a  Fairbanks/Laemmli SDS-PAGE gel of the reaction of 97  ng  I- 
6  125  elastase with lysates of 1.5 x  10  cells, as indicated. Arrow indicates the  I-elastase-inhibitor 
complex of Mr 66,000; E designates unreacted l~SI-elastase. 
FIGURE 4.  Appearance of the elastase inhibitor in monocytes during in vitro culture. Shown 
t25  is an autoradiograph of a  Fairbanks/Laemmli gel containing 130  ng  I-porcine pancreatic 
elastase reacted as indicated with extracts of 1.9 ×  l0  s monocytes cultured for 0 d,  1 d, 3 d, 
5 d, 7 d, or 10d. 
monocytes increased during culture; it was maximal after 5-7 d (Fig. 4), at which 
time the inhibitor activity of monocyte extracts was comparable to that of U937 
cells  (not  shown).  These  findings indicate  that  the  expression  of the  elastase 
inhibitor by monocytes requires a maturation process. 
Elastase Inhibitor in Adherence-Purified Monocytes.  Percoll-purified monocytes 
are  contaminated  with  varying  numbers  of  iymphocytes (see  Materials  and 
Methods). Therefore, it was important to demonstrate that the monocyte is the 
cell that develops the elastase inhibitor on in vitro culture. Adherence to plastic 
tissue culture is an alternate method to separate monocytes from iymphocytes; 
adherence generates monolayers of monocytes in high purity (38, 39). Extracts 
of freshly-isolated adherence-purified monocytes, like extracts of freshly-isolated 
Percoll-purified monocytes, did not form a complex with a/SI-pancreatic elastase. 
Extracts of adherence-purified monocytes that were cultured as monolayers for 
7 d  had elastase-complexing activity that was quantitatively comparable to that 2148  A  FAST-ACTING  ELASTASE  INHIBITOR  1N  HUMAN  MONOCYTES 
FICu~E  5.  Complex formation of l~51-1abeled human neutrophil elastase with a component 
of U937 ceils and cultured monocytes. Shown is an autoradiograph of a  Fairbanks/Laemmli 
gel of 44 ng ~zSI-labeled human leukocyte elastase reacted with extracts of 1.7 ×  106 cells, as 
indicated. 
of  Percoll-purified  monocytes  cultured  for  7  d  (not  shown).  These  findings 
indicate that the monocyte is the cell that acquires elastase inhibitory activity on 
in vitro culture. 
Reaction  of  the  Monocyte/U937  Inhibitor  with  Elastase  of  Human  Neutro- 
phils.  The  serine  elastase of porcine  pancreas,  which  is readily available,  was 
used as the target proteinase in most experiments. The likely physiological target, 
however,  is  the  related  serine  elastase  of human  neutrophils  and  monocytes. 
Therefore, 125I-labeled human neutrophitelastase was used as a target proteinase. 
Extracts  of  U937  cells  formed  a  complex  with  lz~I-neutrophil  elastase  (Mr 
66,000)  (Fig.  5).  This  activity  was  not  detectable  in  freshly-isolated,  Percoll- 
purified monocytes, but extracts of monocytes cultured for 7 d formed a complex 
with ~25I-neutrophil elastase (Fig. 5). 
The Monocyte Inhibitor Is Fast-acting.  The  time  course of the  reaction  with 
~2~I-pancreatic elastase was examined using the extracts of 7-d cultured mono- 
cytes as the source of inhibitor. The reaction was found to be complete after 20- 
40 s at 37°C (Fig. 6).  Identical results were obtained with extracts of U937 cells 
(not shown).  These findings characterize  the inhibitor in monocytes/U937 cells 
as a fast-acting inhibitor of elastase. 
The Monocyte Elastase Inhibitor Is Not aaPI.  We examined whether the elastase 
inhibitor detected in this study is the circulating elastase inhibitor  a~PI, since it 
was previously shown (22) that isolated monocytes synthesize oqPI. When human 
serum, as the source of alPI,  was reacted with  12~I-pancreatic elastase, a major 
complex formed of Mr  80,000.  This  complex did not comigrate with  the  1251- 
elastase  complex  formed  by extracts  of U937  cells  or  monocytes (Fig,  7,  the 
three left lanes), indicating that the monocyte inhibitor and alPI are nonidentical. 
Immune  precipitation  by  two  different  rabbit  antisera  against  human  alPI 
precipitated the complex from serum, but did not precipitate the complex formed 
by  cultured  monocytes  or  U937  cells  (Fig.  7,  the  three  right  lanes).  These 
findings show that the monocyte elastase inhibitor identified in this study is not 
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FIGURE 6.  Time course of the reaction of ~251-pancreatic elastase with the inhibitor in 6-d 
cultured monocytes. Shown is an autoradiograph of a Fairbanks/Laemmli SDS electrophoresis 
gel of 190 ng ~z~I-labeled  pancreatic elastase reacted at 37°C with the extract of 2.5 ×  106 6- 
d  cultured  monocytes for  0-5  rain,  as  indicated.  Note  that  formation of the  ~51-elastase- 
inhibitor complex is complete after 20-40 s.  No further reaction was observed at 5  rain of 
incubation (last lane) or at 20 or 30 min (other experiments, not shown). 
FIGURE 7,  Comparison of the l~51-elastase-a~P1  complex with the ~5I-elastase-U937/mono- 
cyte  inhibitor  complex.  Shown  in  the  left  three  lanes  of  the  autoradiograph  (Fair- 
banks/Laemmli gel) are 130 ng ~I-pancreatic elastase reacted as indicated with 0.5 ttl normal 
human serum, or with the extract of 1.5 x  106 U937 cells, or the extract of 106 6-d cultured 
monocytes. Shown in the right three lanes are replicate reaction mixtures immunoprecipitated 
with rabbit anti-human cqPl antiserum. Note that the antiserum precipitates the serum a~Pl- 
complex,  but  does  not  precipitate  the  complex  formed  by  the  monocyte/U937  inhibitor. 
Identical results were obtained with another rabbit anti-human a~PI antiserum (not shown). 
Discussion 
This is the first characterization  of a  proteinase  inhibitor  molecule  of human 
monocytes that is active against  neutrophil elastase.  The molecule is detected  in 
cultured  monocytes  and the monocyte-like  cell line U937;  it was identified  as a 
proteinase  inhibitor based on its ability to form, with the active site of elastase, a 
complex  that  is  stable  in  boiling  SDS  and  susceptible  to  nucleophilic  cleavage. 2150  A  FAST-ACTING  ELASTASE  INHIBITOR  IN  HUMAN  MONOCYTES 
The quantity of complex formed is dependent on: the concentration of monocyte 
or  U937  extract  (Fig.  2);  the  concentration  of  ~e5I-elastase  (not  shown);  the 
temperature (not shown); and the time of incubation (Fig. 6). The tool wt of the 
elastase inhibitor is estimated at 50,000, which is the M~ of the complex (66,000) 
minus that  of elastase (26,000),  with  10,000 arbitrarily added to represent  the 
inhibitor  fragment  assumed  to  be released on  formation  of the  complex  (36). 
Based on  coelectrophoresis,  the  monocyte inhibitor  appears  to  be the  human 
analog of the guinea  pig component  MPI, an  inhibitor  of elastase and  trypsin 
detected (30) in culture medium and extracts of elicited macrophages. 
It  has  been  reported  (40)  that  certain  proteinase-proteinase  inhibitor  com- 
plexes cannot be detected on Laemmli electrophoresis gels due to their  lability 
in the primary amine Tris at high pH. To avoid base-catalyzed hydrolysis of the 
elastase-elastase inhibitor complex, a Fairbanks/Laemmli hybrid electrophoresis 
system was developed with  lower pH and  lower concentrations  of Tris buffer. 
The  mobilities of pancreatic  elastase and  seven marker  proteins  were propor- 
tional  to  the  log  of their  mol  wt  on  these  Fairbanks/Laemmli  gels.  When 
examined on Fairbanks/Laemmli gels, the conversion of l~5I-elastase  to the l~5I- 
elastase-inhibitor  complex  in  a  reaction  driven  toward  completion  by  excess 
U937 extract was >85%  complete, demonstrating  that  the complex is stable in 
this electrophoresis system. When eight sets of duplicate reaction mixtures were 
examined in parallel on both electrophoresis systems, the ~2~I-elastase conversion 
to  complex  detected  on  Laemmli  gels  was  62%  of  that  detected  on  Fair- 
banks/Laemmli  gels,  indicating  that  partial  hydrolysis  occurs  in  the  former 
system. 
The elastase inhibitor  is detected in  the monocyte-like cell line  U937, but is 
not detected in freshly isolated monocytes. The elastase inhibitor activity becomes 
detectable in monocytes only after in vitro culture; activity is maximal at 5-7 d. 
Human  monocytes  cultured  in  vitro  are  known  to  acquire  macrophage-like 
characteristics; the cells do not divide, but acquire macrophage-like morphology 
and  increase  in  size  (41).  The  amounts  of certain  components  increase  on  in 
vitro maturation of monocytes; these included C2 and factor B (38, 41), and the 
lysosomal  enzymes  /3-glucosaminidase,  /3-glucuronidase,  and  acid  phosphatase 
(42). The amounts of other components, including HLA-DR (43), serine elastase 
(23), and a~PI (22) decrease as the monocyte differentiates in culture. 
As  mentioned  above,  the  high  activity of serine  elastase  measured  in  fresh 
monocyte extracts decreases when monocytes mature in culture,  reaching neg- 
ligible levels at day 6 (27). Both the study of elastase activity (27) and this study 
of elastase  inhibitor  were done  on  unfractionated  cell  extracts.  More  refined 
examination  will  be required  to determine  whether  absolute levels of elastase 
decrease on culture, or absolute levels of elastase inhibitor increase, or whether 
the levels of both are altered. 
This study is the first characterization of the major elastase inhibitor molecule 
of human monocytes. The activity of the elastase inhibitor was detected in several 
earlier  studies,  e.g.  in  the  cytosol fraction  of human  pulmonary  macrophages 
(44). The presence of an elastase inhibitor  in  U937 cells was inferred from the 
increase of elastase activity on fractionation of cell extracts (14). 
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The  content  was estimated  from  the  number  of ~25I-elastase  molecules added 
per reaction and the resulting fraction converted to complex. The estimate that 
this calculation supplies is a minimum estimate because inhibitor molecules may 
fail  to  react,  or  may already  be  complexed  to  proteinase,  or  may  react  with 
nonradiolabeled proteinases in the cell extract. The estimated inhibitor content 
of monocytes cultured for 7 d is _>1.5 X l0  s functional molecules per cell, or 12 
~g per  108 cells. We can, thus, conclude that the elastase inhibitor molecule is a 
major component in monocytes, representing >0.1% of monocyte protein. 
It is interesting to compare the monocyte elastase inhibitor with the circulating 
elastase inhibitor alPI. This study shows that the elastase inhibitor of monocyte 
extracts  is  not  identical  to  ajPI,  since  the  two  do  not  comigrate  on  SDS- 
electrophoresis  (Fig.  7).  Moreover,  the  two are  not  immunologically  related, 
since the monocyte inhibitor  failed to react with heteroantiserum  to aaPI (Fig. 
7).  It was previously shown (22) that synthesis of oqPI by monocytes is greatest 
in  freshly  isolated  cells,  and  declines  during  10  d  in  culture.  This  pattern  is 
opposite to that  observed for the  monocyte elastase  inhibitor,  which increases 
when monocytes mature in culture (Fig. 4). a~PI is plentiful in circulating blood 
plasma (2 mg/ml) (45), whereas the monocyte inhibitor is either absent or present 
in concentrations  too low to be detected in  this  study (Fig.  7,  first lane).  This 
study detected no a~PI  in  monocyte extracts by an assay that  was adequate  to 
detect a~PI in diluted serum (Fig. 7). The lack of detection of oqPI in monocyte 
extracts might be due to its low concentration. 
As discussed above, elastase inhibitor  activity increases as monocytes mature 
in culture into macrophage-like cells similar to those found at inflammatory sites. 
It  is,  thus,  likely  that  the  elastase  inhibitor  is  a  functional  component  of the 
inflammatory  macrophage rather  than  the circulating  monocyte. This fits well 
with the recent finding (17,  18) that elastase activity is required by neutrophils 
(and presumably by monocytes) for movement in response to chemotactic agents 
from the circulation to extravascular sites. At extravascular sites, this function is 
no longer required, and elastase inhibition becomes important.  The rapid reac- 
tion  of the  monocyte  inhibitor  with  elastase,  and  its  high  concentration  in 
matured  monocytes make  this  molecule an  excellent candidate  for regulating 
serine  elastase  activity  at  inflammatory  sites.  Control  of  elastase  activity  at 
inflammatory sites is important  because of the high  concentrations  that  can be 
released, and the large spectrum of proteins susceptible to cleavage (see Intro- 
duction). We have not investigated whether the elastase inhibitor is secreted by 
human  monocytes,  but  MPI,  which  is  the  corresponding  elastase  inhibitor  of 
guinea pig macrophages, was originally detected as a secreted protein (30). 
To establish its physiological role, it will be necessary to determine the activity 
spectrum  of the  monocyte proteinase  inhibitor,  i.e.  to determine  whether  the 
inhibitor has the capacity to act on other proteinases secreted by inflammatory 
cells, including neutrophil cathepsin G (angiotensin-converting enzyme) (46, 47), 
and  macrophage plasminogen  activator  (48),  cytolytic factor (49),  complement 
components  C2  (38) and  factor  Bb (41).  It  is  not  known  whether  other  cells 
express  this  elastase  inhibitor  molecule.  We  can  conclude  that  the  monocyte 
inhibitor is not identical to protease nexin, an inhibitor in human fibroblasts of 
trypsin-like  proteinases  (50),  because  the  latter  is  inactive  against  leukocyte 2152  A  FAST-ACTING  ELASTASE  INHIBITOR  IN  HUMAN  MONOCYTES 
elastase (51).  Comparison with proteinase inhibitors found in other cells (52, 53) 
must await further characterization. We must also determine whether the mon- 
ocyte elastase inhibitor is  the same or related to the inhibitor of plasminogen 
activator detected in human monocytes (48, 54). 
Summary 
A  proteinase inhibitor active against neutrophil and pancreatic elastase was 
detected in extracts of cultured human monocytes and the human monocyte-like 
cell line U937. This component forms a covalent complex with the active site of 
elastase; the complex is stable in boiling sodium dodecyl sulfate solution, and is 
susceptible to nucleophilic cleavage. 
The  activity of the  elastase  inhibitor  is  not  detected in  extracts  of freshly 
isolated monocytes, but becomes detectable when the monocytes are allowed to 
mature  in  culture,  with  maximum levels  occurring at  5-7  d.  The  monocyte 
inhibitor is fast-acting; its reaction with  ~25I-labeled elastase is complete in <1 
min at 37°C. 
Analysis by electrophoresis and studies using a heteroantiserum to at-protein- 
ase inhibitor demonstrated that the elastase inhibitor of monocytes/U937 cells 
is not identical to a~-proteinase inhibitor, the major elastase inhibitor of blood 
plasma.  The  extent  of conversion of ~25I-elastase to  the  ~25I-elastase-inhibitor 
complex is proportional to the amount of U937  extract or cultured monocyte 
extract, indicating that this reaction can serve to quantify the elastase inhibitor. 
The elastase  inhibitor is  an  abundant component in  mature monocytes, with 
_>1.5 x  106 molecules/cell (_>12/~g per 108 cells, >0.1% of total cell protein). Its 
tool wt is estimated at 50,000. 
Thus, the monocyte inhibitor should be classified as a  putative regulator of 
neutrophil (and monocyte) elastase activity at inflammatory sites.  This designa- 
tion is based on the properties of the molecule, including its high concentration 
in  maturing monocytes, its affinity for elastase, and  its  fast reaction with this 
enzyme. 
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